UTHR Add to watchlist $556.82 5.27 (-0.94%) Last updated: May 31, 2026 06:41
52-Week Range
$556.82
$272.12 $556.82 $609.35

Fundamentals Overview

United Therapeutics Corporation is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 20.4 PEG 3.22 P/B 4.1 P/S 7.46

Intrinsic value (DCF)

+44.4% upside vs price

Profitability

Net margin 40.6%

Risk (Beta)

0.6 — lower vol

Earnings & growth

EPS $27.28 Rev -1.1% Profit -24.5% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 71% confidence Risk: Lower Volatility — Beta 0.6. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +44.4% upside vs price · Analyst grade: B+ · Sentiment improving (1 upgrade) · 3M vs Healthcare sector: +9.4%

Pressures (Sell):

3M vs S&P 500: -5.1%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$23.64B
P/E (TTM)
20.41
EPS (TTM)
$27.28
Dividend Yield
N/A
52-Week Range
$272.12 - $609.35
Volume vs Avg
N/A
Beta
0.6

About

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise abili...
Sector: Healthcare
Headquarters: US
Employees: 1,305
IPO Date: Jun 1999
Beta: 0.6 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 13, Equal Weight: 7, Neutral: 2, Outperform: 5, Overweight: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $804.04; current price is $556.82. That’s a +44.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 20.41
DCF value (model) $804.04 (44.4% upside)
PEG (TTM) 3.22
P/B (TTM) 4.1
P/S (TTM) 7.46
P/FCF (TTM) 23.24
Liquidity & enterprise
Current Ratio (TTM) 4.79
Quick Ratio (TTM) 4.5
Cash Ratio (TTM) 1.79
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 40.61%
Gross margin (TTM) 86.58%
Operating margin (TTM) 45.34%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for UTHR.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 13Equal Weight 7Neutral 2Outperform 5Overweight 3
1 upgrade, 0 downgrades
Price Target Consensus
Current $556.82
Median $635.00
Consensus $636.83
Low consensus $516.00
High consensus $735.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Wells Fargo upgrade Equal Weight Overweight 2026-05-07
RBC Capital maintain Outperform Outperform 2026-05-07
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
HC Wainwright & Co. maintain Buy Buy 2026-03-31
B of A Securities maintain Neutral Neutral 2026-03-31
Wells Fargo maintain Equal Weight Equal Weight 2026-03-31
TD Cowen maintain Buy Buy 2026-03-30
Wells Fargo maintain Equal Weight Equal Weight 2026-03-23
Cantor Fitzgerald maintain Overweight Overweight 2026-03-12
UBS maintain Buy Buy 2026-03-05
RBC Capital maintain Outperform Outperform 2026-02-26
HC Wainwright & Co. maintain Buy Buy 2026-02-26
Oppenheimer maintain Outperform Outperform 2026-02-26
Wells Fargo maintain Equal Weight Equal Weight 2026-02-26
TD Cowen maintain Buy Buy 2026-02-26
UBS maintain Buy Buy 2026-01-06
UBS maintain Buy Buy 2025-11-06
RBC Capital maintain Outperform Outperform 2025-10-30
Wells Fargo maintain Equal Weight Equal Weight 2025-10-30
HC Wainwright & Co. maintain Buy Buy 2025-10-30
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-10
UBS maintain Buy Buy 2025-09-29
Cantor Fitzgerald maintain Overweight Overweight 2025-09-10
HC Wainwright & Co. maintain Buy Buy 2025-09-05
Oppenheimer maintain Outperform Outperform 2025-09-05
UBS maintain Buy Buy 2025-09-04
Wells Fargo maintain Equal Weight Equal Weight 2025-09-03
B of A Securities maintain Neutral Neutral 2025-09-02
Jefferies maintain Buy Buy 2025-09-02
UBS maintain Buy Buy 2025-08-13